Influenza

Seqirus is seeking reactogenicity and immunogenicity outcomes between its influenza vaccines and available mRNA vaccines for COVID-19.

Plus: how could the COVID-19 testing market boom improve public flu awareness?

COVID-19 response restrained flu outbreaks last year. An expert explains his concern that won't be enough this winter.

An interview with a study author on new Novavax-Seqirus co-administration trial data, and the future concerns of circulating COIVD-19 and influenza.

The device may help clinicians differentiate between past infections and co-infections during the upcoming flu season.

In a population-based cohort study with a mean follow-up of 3.6 years, childhood outcomes showed no statistically significant associations with any adverse health conditions.

A discussion with the CDC’s Flu Czar, Lynnette Brammer, surrounding the upcoming flu season and what we can expect due to the COVID-19 pandemic.

The government agency will be assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine.

A concerted effort to increase flu vaccination during the COVID-19 pandemic resulted in more protection among a high-risk population, as well as educational opportunities for pharmacy students.

NanoFlu/NVX-CoV2373 elicited functional influenza and COVID-19 antibodies in ferrets 2 weeks after vaccination.

The frontline assay from Abbott will help differentiate among 4 respiratory viruses in real-time.

The authors note that the difference in hospitalization rate may be partly due to existing immunity to influenza in the population.

Investigators are calling for routine use of these tests for patients admitted with acute respiratory symptoms during the influenza season.

New study may help contribute to COVID-19 research.

A recently created therapy for the influenza virus may help aid in the fight against COVID-19.

The new pathogen panel will distinguish between 20 different common and serious respiratory infections, giving clinicians more confidence in flu season diagnoses.

In a national survey, parents responded they would not be getting a vaccine for their kids during the COVID-19 pandemic.

This test simultaneously detects and differentiates between SARS-CoV-2, influenza A and B.

A new analysis of excess deaths suggests the peak of the current pandemic in New York City had a death rate in the same league as the infamous 1918 influenza pandemic.

A study team examined asthma prevalence in patients hospitalized for COVID-19 with population asthma prevalence and a 4-year average of asthma prevalence in influenza hospitalizations across the United States.

Evidence is accumulating that influenza vaccination protection wanes over the course of a single influenza season, with significant implications for public health.

The pharmaceutical company has over 25% more US doses due to the increased anticipation of higher demand because of COVID-19.

A new survey shows parents’ fears of getting kids to their providers for fear of contracting the virus.

David Ho, MD, likens and contrasts the pandemic to 3 other viral outbreaks and their respective responses.

Manufacturers announce their supplies are being sent out for the upcoming season.

Contracting influenza increased the risk for invasive pneumococcal disease in a study conducted across 3 countries.

A model including clinical symptom reports, Internet searches, and emergency room data predict influenza hospitalizations better in affluent vs. poorer communities.

New study findings shed light on the positive effects of baloxavir for preventing influenza spread in household settings.

With the current COVID-19 outbreak, new data about Influenza mortality related to spectator sports should make the professional leagues and fans pause about attending games.

Baloxavir marboxil showed superiority over placebo and similar efficacy to oseltamir in reducing influenza symptoms.